Release Date: October 26, 2021
Expiration Date: October 26, 2022

Activity Overview

Bipolar disorder (BPD) is a lifelong, frequently recurring mood disorder characterized by treatment-resistant depressive episodes and cognitive decline that negatively impact functionality and quality of life in patients with the condition. Many pharmacological treatments for BPD adversely affect cognition, and those that are beneficial can be difficult to use. However, in recent years, new monotherapies and adjunct treatment options have emerged.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Intra-Cellular Therapies, Inc., and Sunovion Pharmaceuticals Inc.

Target Audience

This online educational activity is directed toward psychiatrists, specialty NPs and PAs, and primary care physicians engaged in the care of patients with bipolar depression.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Identify the differential diagnoses for bipolar disorder
Integrate current treatment recommendations into the care of patients with bipolar disorder
Evaluate data on new and emerging treatment options for bipolar disorder depressive symptoms
Discuss psychosocial concerns faced by patients with bipolar disorder and disease outcomes

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

Faculty

Christoph U Correll, MD

Christoph U Correll, MD
Professor, Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research
Medical Director
Recognition and Prevention (RAP) Program, Department of Psychiatry
Zucker Hillside Hospital

Disclosures: Grant research support: Janssen Pharmaceuticals, Takeda Pharmaceutical Company; Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma; Aristo Pharma; Axsome Therapeutics; Darnitsa Pharmaceutical Company; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies; Janssen/Johnson & Johnson; Karuna Therapeutics; LB Pharmaceuticals, Inc.; Lundbeck; MedAvante-ProPhase, Inc.; MedInCell; Medscape; Merck & Co, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan; Neurocrine Biosciences, Inc.; Noven Therapeutics LLC; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Recordati; Relmada Therapeutics, Inc.; Rovi; Seqirus; Servier Laboratories; SK Life Science Inc; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals; Takeda; Teva Pharmaceutical Industries Ltd.; Viatris; Shareholder: LB Pharmaceuticals, Inc.; Other: Royalties from UpToDate, Inc.

Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP
Adult/Family Nurse Practitioner
Owner, Wright & Associates Family Healthcare
Concord and Amherst, New Hampshire

Disclosures: Consultant: GSK - OA/Pain; Pfizer, Sanofi and Merck: Vaccines; Speaker’s Bureau: Pfifzer, Sanofi and Merck: Vaccines; AbbVie and Biohaven: Migraines.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Support